The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: A status report in France in 2011

European Journal of Cancer

Volumn 49, Issue 9, 2013, Pages 2126-2133

  Lievre A ^a,b   Artru, P ^c   Guiu, M ^d   Laurent Puig, P ^e,f   Merlin, J L ^g,h,i   Sabourin, J C ^j   Viguier, J ^k   Bastie, A ^l   Seronde, A ^l   Ducreux, M ^m,n  

^a INSTITUT CURIE   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c Centre Orthopédique Santy Hôpital Privé Jean Mermoz   (France)

^d Anatomy Pathology Office   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g CENTRE ALEXIS VAUTRIN   (France)

^h UNIVERSITÉ DE LORRAINE   (France)

ⁱ CENTRE DE RECHERCHE EN AUTOMATIQUE DE NANCY   (France)

^j HÔPITAL CHARLES NICOLLE   (France)

^k SERVICE DE DERMATOLOGIE   (France)

^l Merck KGaA France   (France)

^m INSTITUT GUSTAVE ROUSSY   (France)

ⁿ UNIVERSITÉ PARIS SACLAY   (France)

more..

Author keywords

Anti EGFR; Colorectal cancer; Genotyping; KRAS mutation; Monoclonal antibody

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; LEVOLEUCOVORIN; OXALIPLATIN;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL EVALUATION; FEMALE; FRANCE; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; GENOTYPE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PYROSEQUENCING; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; FRANCE; GENES, RAS; GENETIC TESTING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PHYSICIAN'S PRACTICE PATTERNS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84877702019     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.02.016     Document Type: Article

References (45)

1. J. Ferlay, D.M. Parkin, and E. Steliarova-Foucher Estimates of cancer incidence and mortality in Europe in 2008 Eur J Cancer 46 4 2010 765 781
2. F. Berrino, R. De Angelis, and M. Sant Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study Lancet Oncol 8 9 2007 773 783
3. A. Verdecchia, S. Francisci, and H. Brenner Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data Lancet Oncol 8 9 2007 784 796
4. A.M. Bouvier, L. Remontet, and G. Hedelin Conditional relative survival of cancer patients and conditional probability of death: a French National Database analysis Cancer 115 19 2009 4616 4624
5. D. Cunningham, Y. Humblet, and S. Siena Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 4 2004 337 345
6. D.J. Jonker, C.J. O'Callaghan, and C.S. Karapetis Cetuximab for the treatment of colorectal cancer N Engl J Med 357 20 2007 2040 2048
7. R.G. Amado, M. Wolf, and M. Peeters Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 10 2008 1626 1634
8. C.S. Karapetis, S. Khambata-Ford, and D.J. Jonker K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 17 2008 1757 1765
9. A. Lievre, J.B. Bachet, and V. Boige KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab J Clin Oncol 26 3 2008 374 379
10. C. Bokemeyer, I. Bondarenko, and A. Makhson Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 5 2009 663 671
11. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 2009 1408 1417
12. C.J. Allegra, J.M. Jessup, and M.R. Somerfield American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy J Clin Oncol 27 12 2009 2091 2096
13. E. Van Cutsem, J. Oliveira, and E.G.W. Group Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 Suppl. 4 2009 61 63
14. European Medicines Agency. Committee for medicinal products for human use, May 2008 plenary meeting, monthly report. < http://www.ema.europa.eu/ docs/en-GB/document-library/Committee-meeting-report/2009/10/WC500006081.pdf. 2008 > [accessed October 9, 2012].
15. Longchamp EN, F. Molecular genetic testing for equal access to targeted therapies in France in 2011. Collection Reports and Summaries, collective volume edited by INCa; 2012.
16. F. Ciardiello, S. Tejpar, and N. Normanno Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia Target Oncol 6 3 2011 133 145
17. F. Bibeau, C. Louvet, and P. Afchain Observational study on conditions for access to the analysis of KRAS mutation in patients with metastatic colorectal cancer receiving panitumumab treatment Bull Cancer 99 7-8 2012 743 751
18. E. Van Cutsem, M. Dicato, and N. Arber Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009 Ann Oncol 21 Suppl. 6 2010 vi1 vi10
19. Thesaurus National de Canrérologie Digestive. Cancer du colon métastatique. Chapitre 4. < http://www.snfge.com/data/ModuleDocument/ publication/5/pdf/TNCD-chapitre-4.pdf.Version14-Oct-2011 > [accessed October 9, 2012].
20. FDA. FDA approves labeling changes for erbitux and vectibix to reflect KRAS status. < http://fightcolorectalcancer.org/research-news/2009/07/fda- approves
21. Institut national du Cancer. Les plateformes et les tests de génétique moléculaire. Mise à jour Janvier 2012. < http://www.e-cancer.fr/soins/plates-formes-hospitalieres-de-genetique- moleculaire/les-plateformes-et-les-tests-de-genetique-moleculaire > [accessed October 9, 2012].
22. F. Bibeau, H. Frugier, A. Denouel, J.C. Sabourin, and F. Boissiere-Michot Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view Bull Cancer 96 Suppl. 2009 S15 S22
23. J.C. Sabourin, A. Lamy, and F. Le Pessot Molecular pathology: about KRAS genotyping in colorectal carcinomas Revue francophone des laboratoires 418 2012 43 46
24. Working Group of the Institut National du Cancer Guidelines for hospital molecular genetics platforms of cancers Ann Oncol 31 3 2011 135 137
25. INCa. Molecular genetics testing for equal access to targeted therapies in France in 2011. Collection Reports and Summaries, collective volume edited by INCa; March 2012.
26. E. Bellon, M.J. Ligtenberg, and S. Tejpar External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds Oncologist 16 4 2011 467 478
27. Z.C. Deans, J. Tull, and G. Beighton Molecular genetics external quality assessment pilot scheme for KRAS analysis in metastatic colorectal cancer Genet Test Mol Biomarkers 15 11 2011 777 783
28. A. Jung, G. Baretton, and M. Dietel The German quality assurance system for the molecular-pathological detection of KRAS mutations in colorectal cancer J Clin Oncol 27 Suppl. 2009 [abstr. 4018]
29. N. Normanno, C. Pinto, and F. Castiglione KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment PLoS One 6 12 2011 e29146
30. J.H. Van Krieken, N. Normanno, and F. Blackhall Guideline on the requirements of external quality assessment programs in molecular pathology Virchows Arch 462 1 2013 27 37
31. N. Lapeyrere, S. Mathoulin-Pelissier, and J.P. Merlio KRAS analysis management: process and delays Ann Pathol 32 2 2012 81 90
32. H. Blons, and P. Laurent-Puig Technical considerations for KRAS testing in colorectal cancer. The biologist's point of view Bull Cancer 96 Suppl. 2009 S47 S56
33. H. Do, M. Krypuy, P.L. Mitchell, S.B. Fox, and A. Dobrovic High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies BMC Cancer 8 2008 142
34. J.H. Van Krieken, A. Jung, and T. Kirchner KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program Virchows Arch 453 5 2008 417 431
35. B. Angulo, E. Garcia-Garcia, and R. Martinez A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma J Mol Diagn 12 3 2010 292 299
36. W. Weichert, C. Schewe, and A. Lehmann KRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histology J Mol Diagn 12 1 2010 35 42
37. D. Tougeron, T. Lecomte, and J.C. Pages Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer J Clin Oncol 30 Suppl. 2012 [abstr. 3520]
38. U. Malapelle, C. Carlomagno, and M. Salatiello KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer Br J Cancer 107 4 2012 626 631
39. D.T. Patil, C.R. Fraser, and T.P. Plesec KRAS testing and its importance in colorectal cancer Curr Oncol Rep 12 3 2010 160 167
40. A.S. Chrestien, A. Harlé, and M. Meyer-Lefebvre Optimization of routine KRAS mutation PCR-based testing procedure for rational individualized first-line-targeted therapy selection in metastatic colorectal cancer Cancer Med 2 1 2012 11 20
41. J.R. Dijkstra, D.A. Heideman, and G.A. Meijer KRAS mutation analysis on low percentage of colon cancer cells: the importance of quality assurance Virchows Arch 462 1 2013 39 46
42. F. Bibeau, H. Frugier, and E. Lopez-Crapez Evaluation du statut KRAS dans le carcinome colorectal metastatique: bilan d'un an d'expérience et points critiques de la phase pré-analytique Journées Francophones d'Hépato-gastroentérologie et d'Oncologie Digestive 2012 [abstr. 4008]
43. A.R. Thierry, F. Mouliere, and S.E.I. Messaoudi Circulating DNA analysis and concordance with tumor section analysis in the detection of KRAS and BRAF point mutations from metastatic colorectal cancer J Clin Oncol 30 Suppl. 2012 [abstr. 10505]
44. S. Misale, R. Yaeger, and S. Hobor Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 7404 2012 532 536
45. L.A. Diaz Jr., R.T. Williams, and J. Wu The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature 486 7404 2012 537 540